Sacubitril: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption=' | <StructureSection load='' size='340' side='right' caption='Sacubitril' scene='10/1001143/Cv/1'> | ||
Sacubitril is an antihypertensive drug used in combination with [[valsartan]]. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril]. | Sacubitril is an antihypertensive drug used in combination with [[valsartan]]. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril]. | ||
Latest revision as of 12:48, 21 January 2024
Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also Sacubitril. Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases.[1] Sacubitrilat inhibits the enzyme neprilysin,[2] which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure–lowering peptides that work mainly by reducing blood volume. (5jmy). . Water molecules are shown as red spheres. .
|
| ||||||||||
ReferencesReferences
- ↑ Solomon SD. "HFpEF in the Future: New Diagnostic Techniques and Treatments in the Pipeline". Boston. p. 48. Retrieved 2012-01-26
- ↑ Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Apr;50(4):401-14. PMID:19934029 doi:10.1177/0091270009343932